Drug Trial Radar · NCT02368691
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Last checked: Nov 19, 2026Latest source record: Nov 18, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
32
Actual
Start
Jun 2015
Primary completion
Sep 22, 2017
Study completion Sep 22, 2017
Sponsor
- Lead sponsor
- GTxIndustry
- Sponsor type
- Industry
- First posted
- Feb 23, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine if GTx-024 is effective and safe in the treatment of patients with advanced, androgen receptor positive triple negative breast cancer (AR+ TNBC).
Conditions
- Triple Negative Breast Cancer
Interventions
GTx-024Drug
GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Benefit Rate, in Centrally Confirmed Androgen Receptor Positive (AR+) SubjectsTime frame: Sixteen (16) weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Holy Cross Hospital
Fort Lauderdale, Florida
Lakeland Regional Health Care/Cancer Center
Lakeland, Florida
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida
St. Vincent Frontier Cancer Center
Billings, Montana
The West Clinic, PC
Memphis, Tennessee
US Oncology / Texas Oncology, P.A.
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.